Literature DB >> 11874883

Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139.

Stephen R Attridge1, Camilla Johansson, Dang D Trach, Firdausi Qadri, Ann-Mari Svennerholm.   

Abstract

A microplate assay for the detection of bactericidal antibodies to Vibrio cholerae O139 is described. The assay is sensitive, highly reproducible, specific, and convenient to perform. It has been used to demonstrate the induction of serum bactericidal antibodies in Vietnamese recipients of an oral, inactivated, bivalent O1/O139 vaccine, as well as in Bangladeshi patients with O139 disease. In both study groups there was a significant inverse correlation between the preexposure level of antibodies in serum and the magnitude of the subsequent bactericidal response. Although infection generated stronger responses than vaccination, the proportion of responders was similar among individuals with low background titers.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11874883      PMCID： PMC119965          DOI： 10.1128/cdli.9.2.383-387.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  15 in total

1.  Oral immunization with Salmonella typhi Ty21a-based clones expressing Vibrio cholerae O-antigen: serum bactericidal antibody responses in man in relation to pre-immunization antibody levels.

Authors:  S Attridge
Journal:  Vaccine       Date:  1991-12       Impact factor: 3.641

2.  Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

3.  Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.

Authors:  D D Trach; P D Cam; N T Ke; M R Rao; D Dinh; P V Hang; N V Hung; D G Canh; V D Thiem; A Naficy; B Ivanoff; A-M Svennerholm; J Holmgren; J D Clemens
Journal:  Bull World Health Organ       Date:  2002       Impact factor: 9.408

4.  A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera.

Authors:  W H Mosley; A S Benenson; R Barui
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

5.  Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.

Authors:  G A Losonsky; Y Lim; P Motamedi; L E Comstock; J A Johnson; J G Morris; C O Tacket; J B Kaper; M M Levine
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

6.  Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh.

Authors: 
Journal:  Lancet       Date:  1993-08-14       Impact factor: 79.321

7.  Susceptibility of Vibrio cholerae O139 to antibody-dependent, complement-mediated bacteriolysis.

Authors:  S R Attridge; F Qadri; M J Albert; P A Manning
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

8.  Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.

Authors:  J G Morris; G E Losonsky; J A Johnson; C O Tacket; J P Nataro; P Panigrahi; M M Levin
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

9.  Spread of Vibrio cholerae O139 Bengal in India.

Authors:  G B Nair; T Ramamurthy; S K Bhattacharya; A K Mukhopadhyay; S Garg; M K Bhattacharya; T Takeda; T Shimada; Y Takeda; B C Deb
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

10.  Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.

Authors:  F Qadri; G Mohi; J Hossain; T Azim; A M Khan; M A Salam; R B Sack; M J Albert; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  1995-11
View more
  10 in total

1.  Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.

Authors:  Peter Ftacek; Victor Nelson; Shousun C Szu
Journal:  Glycoconj J       Date:  2013-08-17       Impact factor: 2.916

2.  Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.

Authors:  Anne L Bishop; Stefan Schild; Bharathi Patimalla; Brian Klein; Andrew Camilli
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

3.  Vibriocidal assays to determine the antibody titer of patient sera samples.

Authors:  Mike S Son; Ronald K Taylor
Journal:  Curr Protoc Microbiol       Date:  2011-11

4.  Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.

Authors:  Wilbur H Chen; Jose Garza; Monique Choquette; Jennifer Hawkins; Amy Hoeper; David I Bernstein; Mitchell B Cohen
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

5.  Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.

Authors:  Kyoung Whun Kim; Soyoung Jeong; Ki Bum Ahn; Jae Seung Yang; Cheol-Heui Yun; Seung Hyun Han
Journal:  J Microbiol       Date:  2017-12-07       Impact factor: 3.422

6.  Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.

Authors:  Young Ok Baik; Seuk Keun Choi; Jae Woo Kim; Jae Seung Yang; Ick Young Kim; Chan Wha Kim; Jang Hee Hong
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

7.  Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.

Authors:  Maria Rosario Z Capeding; Maria Liza Antoinette M Gonzales; Mandeep Singh Dhingra; Naveena Aloysia D'Cor; Venkat Jayanth Midde; Badri Narayan Patnaik; Yaël Thollot; Eric Desauziers
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

8.  A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values.

Authors:  Taylor A Wahlig; Ben J Brintz; Melanie Prettyman; Andrew S Azman; Daniel T Leung
Journal:  Am J Trop Med Hyg       Date:  2021-07-08       Impact factor: 2.345

9.  A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.

Authors:  Dilip Mahalanabis; Anna Lena Lopez; Dipika Sur; Jacqueline Deen; Byomkesh Manna; Suman Kanungo; Lorenz von Seidlein; Rodney Carbis; Seung Hyun Han; Seong Hye Shin; Stephen Attridge; Raman Rao; Jan Holmgren; John Clemens; Sujit K Bhattacharya
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

10.  Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.

Authors:  Suman Kanungo; Anna Lena Lopez; Mohammad Ali; Byomkesh Manna; Deok Ryon Kim; Tanmay Mahapatra; Jan Holmgren; Mandeep S Dhingra; Thomas F Weirzba; G Balakrish Nair; Sujit K Bhattacharya; John D Clemens; Dipika Sur
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.